PAEAN Biotechnology
PAEAN Biotechnology (PAEAN) is a clinical-stage biotech company located in Korea focusing on the development and commercialization of mitochondria as therapeutic agents to fulfil unmet medical needs. PAEAN has been developing novel technologies for mitochondria production and formulation to keep the isolated mitochondria stable.
PAEAN published six mitochondria related papers and has a broad IP portfolio to secure its mitochondria-based technologies and products.
- 15 registered Korean patents with 11 registered overseas patents
- 18 pending Korean patents with 16 PCT application
PAEAN’s main product, MitoTherapy, is an allogeneic mitochondrion derived from cultured stem cells targeting several diseases: Polymyositis/Dermatomyositis (PM/DM), Parkinson’s Disease, hearing loss, ophthalmic diseases, etc.
The first pipeline candidate, PN-101 for PM/DM treatment received IND approval from MFDS (KFDA) in June 2021. It marked the first allogeneic MitoTherapy product candidate in the world approved by the regulatory body. The Phase 1/2a clinical study to demonstrate the safety and efficacy of PN-101 was completed in Q4 2023 and Phase 2b IND application is scheduled for Q4 this year.
For more information, visit: https://www.paeanbio.com
